Stock Price
2.19
Daily Change
4.52%
Yearly
-80.77%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 6,042.00 61.00 1.02% -21.80%
Daiichi Sankyo 2,594.50 27.50 1.07% -28.11%
Abbott 124.69 -1.37 -1.09% 10.39%
Agios Pharmaceuticals 30.36 -0.63 -2.03% -36.42%
Amgen 228.90 -2.40 -1.04% -9.18%
Amarin 3.21 -0.10 -2.88% -49.13%
Avrobio Inc 1.89 0 0% -87.34%
Biogen 225.91 -4.93 -2.14% -16.37%
Bluebird Bio 6.93 -0.61 -8.08% -85.21%
Cerulean Pharma 1.61 0 0% -44.67%
Epizyme 2.19 0.10 4.52% -80.77%
Exelixis 17.03 -0.05 -0.29% -20.12%
Gilead Sciences 67.81 -1.27 -1.84% 1.24%
GlaxoSmithKline 1,633.60 -32.80 -1.97% 19.70%
Glaxosmithkline 44.88 -0.85 -1.85% 18.79%
Ionis Pharmaceuticals 30.32 0.20 0.66% -51.52%
Karyopharm Therapeutics 7.73 0.27 3.55% -48.67%
MacroGenics 12.90 -0.35 -2.64% -42.23%
Merck & Co 80.73 -0.56 -0.68% -0.55%
Mirati Therapeutics 118.34 -2.31 -1.91% -44.42%
Novartis 81.35 -0.11 -0.14% -4.98%
Novartis 88.19 -0.65 -0.73% -8.97%
Pfizer 54.05 0.48 0.90% 48.16%
Regeneron Pharmaceuticals 614.38 -3.60 -0.58% 14.73%
Seattle Genetics 133.06 0.51 0.38% -28.38%
Spectrum Pharmaceuticals 1.01 -0.06 -5.61% -74.37%
Vertex Pharmaceuticals 228.61 -2.43 -1.05% -4.20%
Xencor 34.83 -0.18 -0.51% -27.60%

Indexes Price Day Year
NASDAQ 14154 -186.23 -1.30% 4.61%
US2000 2024 -38.75 -1.88% -5.48%

Epizyme
Epizyme, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization epigenetic treatment for people with cancer and other serious diseases. The Company’s lead product candidate TAZVERIK (tazemetostat) is an oral selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT). AZVERIK is available to the eligible patients and their physicians in the United States through a specialty distribution network. The Company is developing tazemetostat for the treatment of a range of cancer types in multiple treatment settings. Tazemetostat is a pipeline product, which is showing clinical activity as an investigational monotherapy in multiple cancer indications.